Ariagen, Inc.

Ono Pharmaceutical Co., Ltd.

Albany Molecular Research, Inc.

Promentis Pharmaceuticals, Inc.

Takeda Pharmaceutical Company Limited

Mark Allan Wolf

Graham Johnson

David Douglas Manning

Peter Colabuono

Peter Guzzo

Keith Douglas Barnes

Shuang Liu

Ian L Scott

Garry Robert Smith

Christopher Cioffi

Jun Takeuchi

Atsushi Naganawa

Kensuke Kusumi

Joseph Raker

Hiroshi Imoto

Tomoko Yasuhiro

Takayuki Inukai

Haruto Kurata

Michael Neary

Anjan Chakrabarti

Yuichi Inagaki

Vijay Dattaram Pawar

Santhosh Kumar Chittimalla

Kashinath Sadalapure

Yoshiaki Horiguchi

Yasuyo Kodera

Hiroya Takizawa

The present disclosure relates to indole compounds and pharmaceutical compositions thereof, and their use in stimulating the immune system of patients in need thereof and in treating cancer.

Indole compounds and their use

A compound represented by general formula (I) wherein all the symbols are as defined in the specification has a selective S1P5 receptor agonist activity due to having a linker from a phenyl group to a cyclic substituent in a dihydronaphthalene skeleton; i.e., due to having a short linker of one atom or less as L in general formula (I), and can therefore serve as an agent for treating S1P5-mediated disease, e. g., neurodegenerative disease such as schizophrenia. 

Dihydronaphthalene derivative

A compound represented by the general formula (1) has a pyridone ring structure introduced into a pyrrolo pyrimidine skeleton, so that the compound has a strong Axl inhibitory activity. Consequently, the compound can be used as a therapeutic agent for Axl-related diseases including cancers such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases.

Pyrrolo pyrimidine derivative

The invention relates to compounds of the following formula: 

Propionic acids, propionic acid esters, and related compounds

The compounds of the present invention are represented by the following formula (I): wherein the substituents R, R, R, R, (R), R, A, X, and Y are as defined herein. The compounds are useful in methods of treating a disorder which is created by or is dependent upon inhibiting GlyT-1.

Glycine transporter-1 inhibitors, methods of making them, and uses thereof

The invention relates to propionic acids, propionic acid esters, and related compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds for the treatment of various diseases or conditions, including but not limited to diseases and/or conditions of Central Nervous System (CNS).

The present invention relates to derivatives of vinca alkaloids. Pharmaceutical compositions containing these compounds as well as processes of preparation and treatment of various conditions are also disclosed.

Vinca derivatives

A compound represented by the formula wherein R, R, Rand Rare the same or different and each is a hydrogen atom or a substituent; one of Rand Ris a hydrogen atom and the other is a group represented by the formula: &#x2014;C(&#x2550;X)&#x2014;Rwherein X is N&#x2014;O&#x2014;Ror N&#x2014;NH&#x2014;Rwherein Rand Rare the same or different and each is a hydrogen atom or a group bonded via a carbon atom; and Ris a hydrogen atom or a substituent, and the like and a salt thereof have a superior I&#x3ba;B kinase inhibitory activity, and useful as pharmaceutical agents such as agents for preventing or treating diabetes and the like.

6-azaindole compound

Growing community of inventors

Delanson, NY, United States of America

Mark Allan Wolf